Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Perics JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V
Multiple large-scale analyses of observational data, including those comparing GLP-1RAs to SGLT-2 inhibitors and other oral agents, have found no statistically significant association between GLP-1RA use and the exacerbation of DR or the development of sight-threatening retinopathy [92,93,94,95]
LIV Body states free expedited shipping is included - confirm current shipping terms before enrollment
Medical Disclaimer: Retatrutide is an investigational compound and is not FDA-approved
Red flags that should disqualify a vendor Recognizing problematic vendors saves both money and risk
Compounded Medication Notice: Compounded GLP-1 medications referenced in this article are not FDA-approved
)
